33 States Join $3M Gene Therapy Deal for Sickle Cell

Serenity Cole enjoyed Christmas this year relaxing with her family near St. Louis, making crafts and visiting friends. It was a stark contrast to years of holiday seasons interrupted by hospitalizations for sickle cell disease, a genetic condition that caused her debilitating daily pain.

In May, Cole became one of the first Medicaid patients nationwide to receive gene therapy under a revolutionary payment program. The federal government negotiated directly with pharmaceutical companies on behalf of 33 states, Washington D.C., and Puerto Rico, creating a deal where drugmakers only get fully paid if the treatments actually work.

Under this agreement, if the gene therapy fails to deliver results, states receive discounts and rebates from the manufacturers. That's completely different from typical drug purchases, where health insurers pay the full price whether treatments help patients or not.

The treatment Cole received offers a potential cure for the 100,000 primarily Black Americans living with sickle cell disease, which typically shortens lifespans by more than 20 years. Two FDA-approved gene therapies are now available, costing $2.2 million and $3.1 million per patient, not including lengthy hospital stays.

The financial stakes are enormous for Medicaid, which covers roughly half of all Americans with sickle cell disease. With hundreds of cell and gene therapies currently in clinical trials and dozens expected to receive approval soon, this payment model could reshape how America pays for breakthrough medical treatments.

The program represents a rare bipartisan success, started under President Biden and continued by the Trump administration. "This model is a game changer," said Mehmet Oz, the current CMS administrator, announcing the 33-state partnership in July.

For Cole, the results speak for themselves. She's now living without the constant pain that once forced her to cancel plans and miss school.

The Ripple Effect

This outcome-based payment model addresses two critical challenges at once. It makes cutting-edge treatments accessible to Medicaid patients who might otherwise face restrictions, while protecting taxpayers from paying full price for therapies that don't deliver.

Maryland's Medicaid chief medical officer Djinge Lindsay explained the state's enthusiasm simply: "What we care about is whether services actually improve health." Maryland expects to begin accepting patients this month.

The financial protection matters because the initial clinical trials included fewer than 100 patients and followed them for only two years. States needed reassurance they were making sound investments with limited long-term data.

If successful, this approach will likely expand to other expensive therapies, particularly those treating rare diseases. Sarah Emond, CEO of the Institute for Clinical and Economic Review, called it "a worthy experiment" that balances innovation with fiscal responsibility.

Cole's transformation from frequent hospitalizations to pain-free holidays shows the human impact behind the policy innovation. She's not just a patient anymore; she's proof that aligning payment with results can open doors to life-changing care.